… patients with metastatic HER2-positive breast cancer. It specifically enrolled patients … receptor–positive, HER2-positive metastatic breast cancer]. There are other trials … trial [NCT02614794] regimen with capecitabine [Xeloda] plus tucatinib [Tukysa] and …

… patients with HER2-positive metastatic breast cancer. Although unmet needs remain … (Xeloda) for the treatment of patients with HER2-positive metastatic breast cancer who … older with advanced HER2-positive breast cancer; had previously received trastuzumab, …

… available for the treatment of breast cancer: Monoclonal antibodies: These … receptor 2 (HER2) positive breast cancer. These medications are typically … treatment of advanced HER2-positive breast cancer. Capecitabine (Xeloda) and cyclophosphamide (Cytoxan) …

… to chemotherapy in pretreated metastatic breast cancer. While relatively tolerable, they each … -generation sequencing)​ Second line: capecitabine (Xeloda) for 10 months​ Now, MRI … , HER2-negative (HR+/HER2–) breast cancer (BC): final overall survival (OS …

… (HER2)-mutated metastatic breast cancer (mBC). The data … for Medical Oncology Breast Cancer 2025 Annual Meeting … Bristol Myers Squibb], capecitabine [Xeloda; Genetech, Roche], or vinorelbine … with HER2-mutated metastatic breast cancer, particularly those who …

… patients with HER2-positive metastatic breast cancer who had previously received HER2 … advanced or metastatic HER2-expressing breast cancer with an ECOG performance status … ; n = 20), zanidatamab plus capecitabine (Xeloda; n = 19), or zanidatamab plus …

… physician’s choice with capecitabine (Xeloda) or taxane (nab-paclitaxel [ … low or HER2-ultralow metastatic breast cancer, according to additional data from … identify patients with HER2-ultralow breast cancer. Additional Trial Objectives, Findings, and …

… (HER2+) advanced metastatic breast cancer (mBC) with liver … in combination with capecitabine (Xeloda; Genentech) for advanced … positive liver metastatic advanced breast cancer. Front Oncol. April … for HER2-positive metastatic breast cancer: a systematic review …

… receptor 2 (HER2)-mutated breast cancer (BC). The data … when used with capecitabine (Xeloda; Genentech) for patients with … in HER2-mutated metastatic breast cancer: a phase 2 basket … patients with advanced HER2+ breast cancer (HER2CLIMB). Updated August 14 …

… in ESR1-mutated metastatic breast cancer (MBC) management, biomarker … biomarker testing recommendations for breast cancer, but they currently … patients with advanced breast cancer with ESR1 mutations, … , such as capecitabine (Xeloda; Genentech, Inc), might …